Abata Therapeutics Secures Strategic Investment from Bristol Myers Squibb to Advance Autologous Treg Therapy into Clinical Development
Abata Therapeutics
Cell Therapy Developer
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
Scan the code to register and secure limited free tickets
August 17, 2024
eMedClub News
On August 15 local time, Abata Therapeutics (hereinafter referred to as "Abata") announced that it had received an equity investment from Bristol Myers Squibb (hereinafter referred to as "BMS"). This investmentFor Abata TherapeuticsTreg (Regulatory T Cell) TherapyProvided financial support, to assist itsABA-101 ProjectAccelerate into the clinical development stage.
Abata Therapeutics Focuses on Utilizing Treg Therapy to Address Severe Autoimmune and Inflammatory Diseases. Treg cells play a critical role in modulating immune responses, capable of suppressing excessive immune reactions, thereby reducing inflammation and tissue damage. Abata has developed two leading programs with tissue specificity, potency, and durability through the precise regulation of Treg cells.ABA-101 and ABA-201, targeting progressive multiple sclerosis (MS) and type 1 diabetes, respectively.These two diseases are both tissue-specific autoimmune diseases, and there is currently a significant unmet medical need.
Notably, in July 2024, the IND application for Abata Therapeutics' first TCR-Treg candidate drug, ABA-101, was approved by the U.S. FDA. A Phase 1 clinical study targeting progressive MS is expected to commence by the end of this year, while ABA-201 is currently undergoing IND-enabling studies. ABA-101 is Abata's...Through genetic engineering technology, specific TCR genes are inserted into the patient's own Tregs, enabling these Tregs to precisely recognize and target tissue-specific antigens at the site of the disease.Thereby exerting a powerful local immunosuppressive effect while avoiding the side effects of systemic immunosuppression. In addition, the use of autologous Tregs significantly reduces the risk of rejection and enhances the safety and efficacy of the treatment.
In recent years, TCR-engineered Treg cell therapy (TCR-Treg) has become a research hotspot in the field of immunotherapy. Through genetic engineering technology, scientists are able to modify Treg cells to enhance their targeting and specificity, effectively suppressing disease-related immune responses without triggering excessive immune reactions. Based on its promising market potential, Bristol-Myers Squibb's (BMS) investment is undoubtedly a strong endorsement of the future of Treg cell therapy. Meanwhile, BMS’s involvement not only provides Abata Therapeutics with financial support but also brings in BMS’s experience and resources in the field of cell therapy, further accelerating the clinical development and commercialization process of Abata’s drug candidates.
It is worth noting that the research on Treg in China is currently in its early exploratory stage, although it is gaining momentum. At present, some companies have already made moves in this field or have expressed intentions to do so, such asBioland Biotech, Beroni Biotech, Zeland Biotech, VDJBio, and Promab Biotechnologiesetc.
References:
1.https://abatatx.com/abata-therapeutics-announces-strategic-investment-from-bristol-myers-squibb-supporting-advancement-of-its-treg-cell-therapy-pipeline-into-clinical-development/
2.https://abatatx.com/abata-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-clinical-evaluation-of-aba-101-in-progressive-multiple-sclerosis/
Focusing on 13 major cutting-edge tracks in biopharmaceutical innovation, covering eight key stages of drug development, and connecting upstream and downstream enterprises and institutions across the entire industry chain.IBI EXPO 2025 Biopharmaceutical Innovation Industry ConferenceWill beMarch 1, 2025 to March 2, 2025Held at the Suzhou International Expo Center.
Registration and Event Inquiry
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media:Teacher Wang 18701871600
Exciting Live Broadcast Preview
Press and hold to scan the QR code to participate immediately ↓
Recommendation
1
August 21st (Wednesday) 19:00-21:00
"Fly" Beyond Exploration: Focusing on Process Innovation and Development in Stem Cell Therapy
Dian Dian "Share”、“Like" and "In view", charge me up a bit~"